$2.02
-0.02-0.98%
At close: Apr 20, 5:00 PM EST
$2.02
N/A
After Hours: 7:59 PM EST
Esperion Therapeutics Inc Stock Guidance
ESPRNASDAQ
Esperion Therapeutics (ESPR) last issued guidance on January 11, 2026 for fiscal year 2025. The company guided revenue in the range of $400.00M - $408.00M for the period.
Latest Guidance Date
Jan 11, 2026
Guidance Period
Full Year 2025
Revenue Guidance Range
$400.00M - $408.00M
Esperion Therapeutics Guidance History
Review all historical guidance issued by Esperion Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Esperion Therapeutics (ESPR)?
The most recent guidance for Esperion Therapeutics (ESPR) was reported on January 11, 2026 for the fiscal year 2025. Esperion Therapeutics forecasted revenue between $400.00M and $408.00M for the period.
What revenue range did Esperion Therapeutics (ESPR) guide for?
Esperion Therapeutics (ESPR) guided revenue in the range of $400.00M to $408.00M for the fiscal year 2025.
When did Esperion Therapeutics (ESPR) last issue guidance?
Esperion Therapeutics (ESPR) last issued guidance on January 11, 2026 for the fiscal year 2025.
